Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active pouchitis (defined as having a PDAI score \> 7) after IPAA for UC, despite at least 14 days of antibiotic therapy. Active pouchitis must be confirmed by endoscopy and histology within 4 weeks of study entry~* Able to give informed consent~* Able and willing to comply with all study procedures~Exclusion Criteria:~* Patients previously treated with infliximab or any investigational immunosuppressant/ immunomodulator for pouchitis~* Patients undergoing chemotherapy for the treatment of cancer~* Presence of other inflammatory diseases of the pouch: Crohn's disease, Cuffitis, active specific infection of the pouch: (e.g., CMV, C. difficile)~* History of non-inflammatory disease of the pouch: decreased pouch compliance, irritable pouch syndrome, afferent or efferent limb obstruction, stricture of pouch~* Ileal pouch patients with familial adenomatous polyposis~* History of other diarrheal illnesses: lactose intolerance, celiac disease, small bowel bacterial overgrowth~* Primary Sclerosing Cholangitis with or without liver transplant~* Uncontrolled systemic disease~* Needing oral or topical 5-ASA, cholestyramine, steroids or immunomodulators~* Other major physical or major psychiatric illness within the last 6 months that in the opinion of the investigator would affect the patient's ability to complete the trial~* Women who are pregnant, breast feeding, or planning to become pregnant during the study~* Women of child-bearing potential who are not willing to use barrier or depot contraception methods~* Use of NSAIDs or aspirin (\>3 times per week) within the past 3 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Active treatment with AST-120

Based on this trial design, predict the completion outcome and termination type (if applicable).